Litigation

Blue Cross and Blue Shield Association v. Celgene Corporation

terminated/transferred

1:20-cv-01980

Filed
2020-07-21
Terminated
2021-04-18

Patents at issue (1)

Summary

Clayton Act antitrust action by Blue Cross and Blue Shield Association against Celgene, referencing the '106 patent as part of Celgene's Revlimid patent portfolio/alleged monopolization scheme. The case was terminated/transferred, with an aggregator-listed termination date around April 18, 2021.

Case overview & background

Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Key legal developments & outcome

Major rulings, motions, claim construction, settlements, and the present posture or final disposition.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

In the news

What the press has reported about this case, summarized with links to the source articles.

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Plaintiff representatives

Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).

Defendant representatives

Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).

Save related patent research

Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).